A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: The INTENSE study

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1374-1378

  Clotet, Bonaventura ^a   Capetti, Amedeo ^b   Soto Ramirez, Luis E ^c   Gatell, Jose M ^d   Rowell, Lucy ^e   Salgo, Miklos ^e   Schapiro, Jonathan M ^f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Sheba Medical Center ^*  (United States)

^f SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiretroviral; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL MONITORING; LIVER FAILURE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTICENTER STUDY; PAROTITIS; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SURGICAL INFECTION; VIRUS TYPING;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 56649119165     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn377     Document Type: Article

References (9)

1. Lalezarl JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
2. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
3. Nelson M, Arasteh K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404-12.
4. Molto J, Ruiz L, Valle M et al. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 2006; 11: 47-51.
5. Havlir DV, Strain MC, Clerici M et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77: 11212-9.
6. Ramratnam B, Ribeiro R, He T et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35: 33-7.
7. Louie M, Hogan C, Di Mascio M et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003; 187: 896-900.
8. McColl DJ, Margot NA, Wulfsohn M et al. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2004; 37: 1340-50.
9. Kolber MA, Saenz MO, Tanner TJ et al. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clin Immunol 2008; 126: 315-21.